TDTara L. DuPont

Tara L. DuPont

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Tara L. DuPont has a total of 94 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Neurodevelopmental therapy in NICUs that care for infants with bronchopulmonary dysplasia

    by Sara B. DeMauro, Meghan Burkhardt, Melissa Hanin, Audrey N. Miller, Melissa House, Meaghan Ransom, Tara DuPont, Megan Lagoski, Audrey Wood, Brianna K. Brei, et al.

  • Open Access

    Neuroactive Medication Exposure Across Neonatal Intensive Care Units of a Large, Multistate Healthcare System

    by Daley Owens, Timothy Bahr, Ariel Tarrell, Brian Winther, Tara Dupont, Jared Olson, Shelley Lawerence

    Objective To characterize prescribing practices and predictors of neuroactive medication exposure in NICU patients. Study Design This was a retrospective cohort study of 16 968 infants receiving care in five NICUs over six years. We summarized infant exposure to opioids, sedatives, or psychotropics, and evaluated factors that predicted medication exposure and drug exposure patterns over time. Result Of the 17 159 infants admitted to a NICU, 3 032 (18%) were exposed to at least one drug of interest. Lower gestational age (aOR 0.82 per week, 95% CI 0.81–0.83) and White race (aOR 1.28, 95% CI 1.18–1.39) were associated with exposure (both p < 0.001). The rates of dexmedetomidine, ketamine, clonidine, and fentanyl exposure increased over time. Lorazepam, midazolam, and pentobarbital rates decreased. Conclusion Neuroactive medication use has changed over time. Exposure is most common in premature infants, underscoring the urgent need for clinical trials to establish their safety and efficacy.

  • Open Access

    Sedative use in infants with grade 3 bronchopulmonary dysplasia (BPD) and associations with neurodevelopmental therapies

    by Thomas J. Davis, Gangaram Akangire, Brianna K. Brei, Matthew Coyle, Bridget DiPrisco, Tara DuPont, Susan Gage, Melissa Hanin, Melissa House, Khanh Lai, et al.

    Background/Objectives: To characterize sedative and analgesic use in NICU patients with grade 3 bronchopulmonary dysplasia (BPD) in relation to respiratory support and neurodevelopmental therapies. Subjects/Methods: Point-prevalence survey across 22 NICUs of infants <24 months corrected age with grade 3 BPD who had never been discharged. Exclusions included recent sepsis, tracheostomy, or major surgery. Data were analyzed descriptively. Results: Among 141 infants, 97 (69%) received ≥1 sedative within 48 hours; 73 (75%) received multiple (mean 2.8 ± 1.6). Alpha-agonizts (n=67) and benzodiazepines (n=65) were most common, with 27 infants receiving an alpha-agonist, opioid, and benzodiazepine combination. Sedative exposure and medication count correlated with higher respiratory support (p<0.001) and FiO₂ (r=0.28, p<0.01). Sedation was associated with fewer completed therapy sessions (z=3.3, p<0.001). Conclusion: Sedation and polypharmacy were frequent among infants with severe BPD and linked to reduced therapy participation, highlighting the need to assess prescribing rationale and neurodevelopmental impacts.


  • Method of home tube feeding and 2–3-year neurodevelopmental outcome

    by Allison Fisher, Anna Ermarth, Con Yee Ling, Kristin Brinker, Tara L. DuPont

    Objective To describe the Bayley Scales of Infant Development 3rd Edition (Bayley-III) of infants discharged home receiving tube feeds. Study design Retrospective review of infants discharged with nasogastric or gastrostomy tube feeds and completed a Bayley-III assessment at 2–3-years of age through a neonatal follow-up program. Results were reported using descriptive statistics. Results Of infants discharged with nasogastric feeds, median Bayley-III scores were in the low-average to average range, and full oral feeds were achieved in 75%. Of infants discharged with gastrostomy tube feeds, median Bayley-III scores were in the extremely low range, and full oral feeds were achieved in 36%. Our data set did not demonstrate a distinct patient demographic that correlated to the type of feeding tube at discharge. Conclusion Neurodevelopmental outcome at 2–3 years does not appear to be negatively impacted by the decision to discharge an infant from the NICU with home NG feedings.


  • Open Access

    Method of Home Tube Feeding and 2–3-year Neurodevelopmental Outcome

    by Tara Dupont, Allison Fisher, Con Yee Ling, Anna Ermath, Kristin Brinker

    Objective: To describe the Bayley Scales of Infant Development 3rd Edition (Bayley-III) of infants discharged home receiving tube feeds Study Design: Retrospective review of infants discharged with nasogastric or gastrostomy tube feeds and completed a Bayley-III assessment at 2-3-years of age through a neonatal follow-up program. Results were reported using descriptive statistics. Results: Of infants discharged with nasogastric feeds, median Bayley-III scores were in the low-average to average range and full oral feeds were achieved in 75%. Of infants discharged with gastrostomy tube feeds, median Bayley-III scores were in the extremely low range and full oral feeds were achieved in 36%. Our data set did not demonstrate a distinct patient demographic that correlated to the type of feeding tube at discharge. Conclusion: Neurodevelopmental outcome at 2–3 years does not appear to be negatively impacted by the decision to discharge an infant from the NICU with home NG feedings.

  • A quality improvement initiative for neonatal hypoglycemia screening and management in a level III neonatal intensive care unit

    by Whitley N. Hulse, Krista Schulte, Victoria Eickelkamp-Marron, Hannah Redder, Jessica M. Davidson, Belinda Chan, Carrie Torr, Tara L. DuPont, Peter H. Grubb

    Objective To bring screening and management of neonatal hypoglycemia in alignment with the 2011 AAP hypoglycemia clinical report Methods A multidisciplinary team developed a quality improvement initiative for neonatal hypoglycemia in neonates ≥35 weeks gestational age in a Level III neonatal intensive care unit between July 2020 and December 2021. A key driver diagram identified interventions for plan-do-study-act testing with corresponding measures to implement a hypoglycemia management protocol and improve adherence to AAP guidelines. Results Time to first blood glucose measurement increased from 49.8 to 122.7 min of life and time to first enteral feed decreased from 14.2 to 3.6 h of life. Neonates receiving intravenous dextrose decreased from 97.1 to 24.7% and discharge rates as a mother-neonate dyad increased from 35 to 62.4%. Conclusions Adherence to the AAP guidelines improved during testing and implementation of a hypoglycemia protocol and was associated with an increased mother-neonate dyad discharge rate.


  • Blanket temperature during therapeutic hypothermia and outcomes in hypoxic ischemic encephalopathy

    by John Flibotte, Abbot R. Laptook, Seetha Shankaran, Scott A. McDonald, Mariana C. Baserga, Edward F. Bell, C. Michael Cotten, Abhik Das, Sara B. DeMauro, Tara L. DuPont, et al.

    Objective Determine whether blanket temperatures during therapeutic hypothermia (TH) are associated with 18–22 month outcomes for infants with hypoxic ischemic encephalopathy (HIE). Study design Retrospective cohort study of 181 infants with HIE who received TH in two randomized trials within the Neonatal Research Network. We defined summative blanket temperature constructs and evaluated for association with a primary composite outcome of death or moderate/ severe disability at 18–22 months. Results Each 0.5 °C above 33.5 °C in the mean of the highest quartile blanket temperature was associated with a 52% increase in the adjusted odds of death/ disability (aOR 1.52, 95% CI 1.09–2.11). Having >8 consecutive blanket temperatures above 33.5 °C rendered an aOR of death/disability of 5.04 in the first 24 h (95% CI 1.54–16.6) and 6.92 in the first 48 h (95% CI 2.20–21.8) of TH. Conclusions Higher blanket temperature during TH may be an early, clinically useful biomarker of HIE outcome.


  • Darbepoetin as a neuroprotective agent in mild neonatal encephalopathy: a randomized, placebo-controlled, feasibility trial

    by Tara L. DuPont, Mariana Baserga, Jean Lowe, Tara Zamora, Sandra Beauman, Robin K. Ohls

    Objective To assess the feasibility and safety of one dose of Darbepoetin alpha (Darbe) administered to neonates ≥34 weeks with mild neonatal encephalopathy (NE). Methods Randomized, masked, placebo-controlled study including neonates ≥34 weeks gestation with mild NE. Neonates were randomized to receive one dose of Darbe (10 μg/kg IV) or placebo. Clinical and laboratory maternal and newborn data were collected. The Bayley Scales of Infant and Toddler Development, third edition (Bayley-III) and a standardized neurological examination at 8–12 months of corrected age were assessed. Results There were no differences in baseline characteristics of the 21 infants randomized (9 Darbe, 12 placebo). Adverse events were not reported at any time. Bayley-III scores were average in both Darbe and placebo groups. Conclusion This study demonstrates that a randomized, masked, placebo-controlled trial is safe and feasible. A large, randomized trial is warranted to assess the effect of Darbe in this population.


  • The impact of the Baby Friendly Hospital Initiative on neonatal hypoglycemia

    by Marina S. Oren, Whittney D. Barkhuff, Andrei Stefanescu, Beatrice M. Stefanescu, Tara L. DuPont

    Objective To assess Neonatal Intensive Care Unit (NICU) admissions for hypoglycemia after the introduction of the Baby Friendly Hospital Initiative (BFHI), followed by implementation of American Academy of Pediatrics recommended hypoglycemia guidelines. Study design Retrospective review of NICU admissions for hypoglycemia. Eligible subjects were healthy infants >35 weeks gestation transferred to a NICU for hypoglycemia. Infants admitted with other pathologies were excluded. NICU admissions from 3 different 18-month epochs (1 = pre-BFHI; 2 = post-BFHI; 3 = post-BFHI+hypoglycemia guidelines) were compared. Results After implementation of BFHI there was a statistically significant increase in admissions for hypoglycemia (Epoch 2 = 1.23% vs Epoch 1 = 0.55%, p < 0.001). Followed by a decrease in admissions after the implementation of hypoglycemia guidelines (Epoch 2 = 1.23% vs Epoch 3 = 0.76%, p = 0.03). Conclusion NICU admissions for hypoglycemia increased with the BFHI. Hypoglycemia guidelines decreased NICU admissions, but not to the pre-BFHI baseline.


  • Evaluating emergency‐release blood transfusion of newborn infants at the Intermountain Healthcare hospitals

    by Timothy M. Bahr, Tara L. DuPont, Thomas R. Christensen, Terry Rees, Elizabeth A. O'BRien, Sarah J. Ilstrup, Robert D. Christensen

    BACKGROUND: An emergency‐release blood transfusion (ERBT) protocol (uncrossmatched type O‐negative red blood cells, AB plasma, AB platelets) is critical for neonatology practice. However, few reports of emergency transfusions are available. We conducted an ERBT quality improvement project as a basis for progress.STUDY DESIGN AND METHODS: For each ERBT in the past 8 years, we logged indications, products, locations and timing of the transfusions, and outcomes.RESULTS: One hundred forty‐nine ERBTs were administered; 42% involved a single blood product, and 58% involved two or more. The incidence was 6.25 ERBT per 10,000 live births, with a higher rate (9.52 ERBT/10,000) in hospitals with a Level 3 neonatal intensive care unit (NICU) (p < 0.001). Seventy percent of ERBTs were administered in a NICU and 30% in a delivery room, operating room, or emergency department. Indications were abruption/previa (32.2%), congenital anemia (i.e., fetomaternal hemorrhage; 15.4%), umbilical cord accident (i.e., velamentous insertion; 15.0%), and bleeding/coagulopathy (12.8%). Fifty‐eight percent of those with hemorrhage before birth did not have a hemoglobin value reported on the umbilical cord gas; thus, anemia was not recognized initially. None of the 149 ERBTs were administered using a blood warmer. The mortality rate of recipients was 35%.CONCLUSION: Based on our findings, we recommend including a hemoglobin value with every cord blood gas after emergency delivery to rapidly identify fetal anemia. We also discuss two potential improvements for future testing: 1) the use of a warming device for massive transfusion of neonates and 2) the use of low‐titer group O cold‐stored whole blood for massive hemorrhage in neonates.